<DOC>
	<DOCNO>NCT02736227</DOCNO>
	<brief_summary>Most patient get liver transplant must take immunosuppressant rest life . However , occur expense chronic CNI toxicity , e.g . chronic kidney disease ( CKD ) , metabolic complication , infection malignancy . Everolimus ( EVL ) drug may stabilize improve kidney function patient chronic kidney disease ( CKD ) cause immunosuppressant . EVL use standard care treatment prevent transplant liver rejection combination immunosuppressant , tacrolimus . The overall aim study examine combination two different immunosuppressant EVL determine patient may stabilize and/or improve kidney function without liver rejection . This study look safe slowly withdraw one anti-rejection medication continue take medicine , whether do without liver rejection occurrence .</brief_summary>
	<brief_title>Biomarkers Predicting Successful Tacrolimus Withdrawal Everolimus ( Zortress ) Monotherapy Early After Liver Transplantation</brief_title>
	<detailed_description />
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Adult LT candidate â‰¥ 18 year age Listed recent ( within 1 month ) recipient decease live donor liver transplantation Combined previous organ transplantation Human immunodeficiency virus ( HIV ) infection Inability provide inform consent comply protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>89 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>liver transplantation</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>everolimus</keyword>
	<keyword>tacrolimus</keyword>
	<keyword>kidney function</keyword>
	<keyword>liver function</keyword>
	<keyword>biomarkers</keyword>
</DOC>